MDMA shows promise for the treatment of post-traumatic stress disorder. Combining the use of Ecstasy with psychotherapy treatments resulted in a reduction of PTSD symptoms after just one session. 54% of the study participants no longer met the PTSD criteria after two sessions. Patients also reported improvements in depression symptoms.
A new study in Neuroscience of Consciousness adds weight to previous findings about the potential benefits psychedelics could have for treating mental health disorders.
A new study challenges existing theories about how benzodiazepines, such as valium, work to calm nerves. Researchers report a 'sticky' gene called Shisa7 plays a critical role in the regulation of inhibitory neural circuits, and the sedative effects benzodiazepines have on circuit activity.
Researchers report synthetic marijuana products, sold under names such as K2 or Spice, have serious side effects including psychosis, seizures and even death. Researchers warn they are not a safe substitute for cannabis.
As with other psychedelics, salvinorin A increased activity across the brain. However, salvinorin A use resulted in more random and disconnected signaling in the default mode network, a brain network associated with relaxing and daydreaming.
PsychLight, a newly developed genetically encoded fluorescent sensor, helped researchers identify a psychedelic compound that acts on beneficial neural pathways to treat psychiatric disorders without the hallucinogenic effect.
Alpha-2-adrenergic agonists appear to be effective at reducing symptoms associated with ADHD in preschool-aged children, and have fewer side effects than traditional stimulants used to treat ADHD.
A new study of male guppies reveals behaviors affected by methylphenidate hydrochloride (MPH), an active ingredient in common ADHD medications, can be passed along to future generations.
A new study reveals ADHD increases the risk of sexually transmitted infections in adolescents threefold compared to the general population. However, the use of ADHD medications reduces the risk of STIs in males by up to 41%.
Lisdexamfetamine (Vyvanse), a medication commonly used to treat ADHD, lowers the risk of hospitalization and death for those with amphetamine use disorder.
Patients with major depressive disorder who experienced trauma during childhood see symptom improvement following psychopharmacological intervention, psychotherapy, or a combination of both.